FFFrancesca Faustini

Francesca Faustini

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Francesca Faustini has a total of 66 co-authors. Here are the top co-authors by number of shared publications:

  • Iva Gunnarsson

    Rheumatology unit, Department of Medicine Solna, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden

    6 shared publications
  • Elisabet Svenungsson

    Karolinska University Hospital, Karolinska Institutet Division of Rheumatology, Department of Medicine, Solna Stockholm

    4 shared publications
  • Agneta Zickert

    Department of Medicine, Division of Rheumatology, Karolinska Institutet, Solna, Sweden

    2 shared publications
  • Anders Larsson

    Department of Medical Sciences/Clinical Chemistry, Uppsala University, Uppsala, Sweden

    2 shared publications
  • Iva Gunnarsson

    Karolinska University Hospital Department of Rheumatology Stockholm

    2 shared publications
  • Vivianne Malmström

    Division of Rheumatology, Department of Medicine Karolinska Institutet, Karolinska University Hospital Solna Stockholm Sweden

    2 shared publications

Latest Publications

  • Open Access

    Oral Glucocorticoid Dose Patterns and Organ Damage in Systemic Lupus Erythematosus—A Nationwide Cohort Study

    by Annica Dominicus, Álvaro Gomez, Ngoc V. Nguyen, Karin Blomkvist Sporre, Francesca Faustini, Elisabet Svenungsson, Elizabeth V. Arkema

    Objective: Evaluating the relationship between glucocorticoid (GC) exposure and organ damage in systemic lupus erythematosus (SLE) is challenging because GC dose varies over time. It is unclear which exposure time window captures the full impact of GC usage. Methods: We studied a nationwide cohort of individuals with newly diagnosed SLE from 2006–2022, with follow‐up until January 2024, through a linkage of Swedish national registers. Long‐term oral GC exposure was assessed from pharmacy dispensations to identify which dosing patterns had the strongest association with organ damage overall, and within the ocular, cardiovascular, peripheral vascular, gastrointestinal, diabetes, and malignancy domains. We used weighted cumulative exposure models to estimate the weights of the average daily dose at different time points and determine the relative importance of exposure on organ damage accrual, adjusted for confounders. Results: Among 3,749 patients with newly diagnosed SLE (82.1% female, median age 48.0 years), the increased risk of first organ damage overall associated with GC dosing was well captured by the past two years (adjusted hazard ratio [HR] 1.42, 95% confidence interval [CI] 1.31–1.53, for 5 mg/day), and fairly well captured by the past one year (adjusted HR 1.34, 95% CI 1.23–1.42, for 5 mg/day). For cardiovascular damage, dose patterns over the past three years substantially contributed to the associated increased risk. Conclusion: In evaluations of overall organ damage in SLE, GC exposure during at least the previous year should be considered to capture the associated increased risk. For cardiovascular damage, the time window for assessing GC exposure and disease activity should be extended to the last three years.

  • Open Access

    Genetic and epigenetic determinants of relapse risk in lupus nephritis

    by Elisabeth Skoglund, Oliver Skoglund, Holme Vestin, Nina Oparina, Ahmed Sayadi, Francesca Faustini, Elisabet Svenungsson, Lars Ronnblom, Maria K Svensson, Juliana Imgenberg-Kreuz, et al.

    Objective: Lupus nephritis (LN) is a potentially severe manifestation of SLE, often resulting in permanent kidney damage. We investigated whether polygenic and/or epigenetic risk is associated with time to LN relapse and whether this association differs by initial therapy. Methods: Caucasian patients with biopsy-verified LN between 1974 and 2022 (n=149) were genotyped using the Illumina Global Screening Array, and DNA methylation was assessed with the Illumina HumanMethylation450k BeadChip. A weighted Polygenic Risk Score (PRS) based on 55 non-Human leukocyte antigen (HLA) SLE risk gene variants and a Methylation Risk Score (MRS) based on the 17 most differentially methylated cytosine-phosphate-guanine sites identified in SLE-control comparison were calculated. Time to LN relapse was analysed using Cox proportional hazards models, adjusted for centre, sex and year of the first LN. Results: Neither PRS nor MRS was associated with time to LN relapse in the overall cohort, irrespective of treatment (PRS: HR=1.00 (0.77–1.30); p=0.99; MRS: HR=1.01 (1.00–1.02); p=0.21). No associations were observed among cyclophosphamide (CYC)-treated patients (PRS: HR=0.81 (0.55–1.20); p=0.29; MRS: HR=1.00 (0.99–1.02); p=0.89). In non-CYC-treated patients, PRS showed a non-significant trend towards shorter time to LN relapse (HR=1.26 (0.88–1.81); p=0.21), with a similar trend for MRS (HR=1.02 (1.00–1.03); p=0.066). Adding MRS to the PRS model improved performance in this subgroup (likelihood ratio test, p=0.028), with significant associations for MRS (PRS: HR=1.56 (0.97–2.50); p=0.066; MRS: HR=1.02 (1.00–1.04); p=0.037). Conclusions: Genetic and epigenetic susceptibility appears to influence LN relapse risk in a treatment-dependent manner. The absence of an association among patients receiving CYC suggests that initial treatment with CYC may attenuate the impact of genetic and epigenetic predisposition on relapse. These findings support the potential of genetic and epigenetic profiling at LN diagnosis to improve relapse risk stratification and individualise selection of treatment.

  • Open Access

    CD72 downregulation on DN2 B cells is associated with disease activity and resistance to rituximab in systemic lupus erythematosus

    by Kittikorn Wangriatisak, Wenqi Huang, Giorgio Sechi, Vilija Oke, Karine Chemin, Caroline Grönwall, Iva Gunnarsson, Vivianne Malmström, Francesca Faustini

    In SLE, expanded B cell subtypes like double-negative 2 (DN2) may harbour autoreactivity, which may be linked to impaired checkpoint regulation. We investigated checkpoint molecule CD72 on B cells, its clinical associations, and dynamic changes upon rituximab (RTX) treatment. Thirty SLE patients (26 with active disease) were studied. Seven received RTX treatment with sampling at baseline, 3 months and 6 months. B cell phenotypes were analysed using spectral flow cytometry, and clinical associations were evaluated. B cell receptor (BCR) signalling was studied through downstream phosphorylation in vitro. Patients with active SLE showed increased frequencies of CD72-negative B cells in switched memory (SWM), activated naïve (aNAV), DN2 and plasmablast (PB) subsets compared with healthy controls (HCs). CD72-negative DN2 cells (CD27-IgD-CD21-CD11c+) were elevated in LN patients. These cells expressed higher CD95 and lower CD20 compared with HCs and canonical SLE DN2. Upon BCR stimulation, lupus CD72-negative SWM and DN2 B cells displayed increased pSYK phosphorylation compared with their CD72-positive counterparts and the overall cell population. CD72-negative DN2 frequencies associated positively with SLEDAI-2K and inversely with C3 levels and were increased in anti-dsDNA-positive patients. After RTX treatment, the remaining DN2 cells were primarily CD72-negative at 3 months. The DN2 B cell subset have been associated with autoimmunity. We showed that DN2 B cells in SLE have reduced CD72 expression, which is associated with anti-dsDNA positivity, complement consumption, and enhanced BCR downstream signalling. The relative resistance of CD72-negative B cells to RTX indicates that an impaired checkpoint programme in lupus B cells may potentially contribute to disease relapse. These findings require validation in larger cohorts.


  • Open Access

    Association between peripheral activated naive and double negative 2 B‐cell subsets and clinical parameters in lupus nephritis patients

    by Kittikorn Wangriatisak, Charlotte de Vries, Ravi Kumar Sharma, Wenqi Huang, Caroline Grönwall, Prapaporn Pisitkun, Iva Gunnarsson, Vivianne Malmström, Patchanee Chootong, Francesca Faustini

    Altered composition of B‐cell compartments is a known feature in patients with systemic lupus erythematosus (SLE). However, deep characterisation of B‐cell subsets and their relation to clinical manifestations and disease activity in patients is limited. In this study, we analysed peripheral B‐cell subsets phenotype in SLE (n = 35) and healthy controls (HCs, n = 15) by spectral flow cytometry. Disease activity was stratified as inactive (SLEDAI‐2 K score 0, n = 2), mild (SLEDAI‐2 K score 1–5, n = 12), moderate (SLEDAI‐2 K score 6–10, n = 6) or high (SLEDAI‐2 K > 10, n = 15). An elevated proportion of activated naive (aNAV), double negative 2 (DN2) and plasmablasts (PB) was observed in patients with high disease activity, compared to other groups of patients and HCs. An upregulation of BTLA was found on both aNAV and DN2 and shifted to lower levels with increasing disease activity. In lupus nephritis (LN) patients (n = 21), aNAV B‐cells were especially expanded and positively correlated with DN2 (r = 0.5, p = 0.019) and PB (r = 0.43, p = 0.048). Also, correlation was observed between DN2 and PB (r = 0.6, p = 0.003). Moreover, aNAV frequencies positively correlated with SLEDAI‐2 K score, and negatively with the complement fractions C3 and C4. Further, aNAV, DN2 and PB were more expanded in association with positive anti‐dsDNA antibodies, rather than other antibody specificities (anti‐Sm). These data suggest roles of extrafollicular B cells as key players in disease development of LN. Their association with presence of anti‐dsDNA antibodies may indicate their value as candidate biomarkers of kidney involvement in SLE.


  • Open Access

    Urinary aberrations in systemic lupus erythematosus not always indicative of lupus nephritis: a cross-sectional cohort study

    by Linnea Karlsson, Agneta Zickert, Elisabet Svenungsson, Jan Schmidt-Mende, Francesca Faustini, Iva Gunnarsson

    Introduction: Kidney biopsy is the reference tool for diagnosing and guiding treatment strategies in inflammatory renal diseases, such as lupus nephritis (LN). We investigated the histopathological findings in first-time kidney biopsies from a large cohort of SLE patients. We focused on the occurrence and type of histopathological findings other than LN, and fulfillment of renal criteria in established SLE classification systems were analyzed. Methods: We retrospectively included SLE patients (n = 139) who underwent a first kidney biopsy between 1995 and 2021, upon clinical suspicion of renal involvement. Based on histology, two groups were defined, LN and non-LN, for which clinical and laboratory features were compared. Results: Findings consistent with LN according to ISN/RPS classification system were present in 123/139 patients (88.5%) and findings not consistent with LN were present in 16 /139 (11.5%). Non-LN patients were older at SLE diagnosis compared to LN patients (M, years 38.0 vs. 30.1, p=0.013) and had longer disease duration (M, years 11.9 vs 0.5) (p=0.027). Among non-LN patients 85.7% met the SLICC criteria item for renal SLE, seen in 94.7% in the LN group (ns). For the ACR/EULAR criteria, 66.7% of the non-LN group fulfilled the criteria compared to 74.8% in LN patients (ns). Proteinuria below the criteria cut-off level (< 0.5 g/24 h) was seen in 20% of patients with class III/IV LN. Conclusion: Our data confirm the importance of kidney biopsy for ruling out the presence of renal pathology other than LN. Patients with low-grade proteinuria may exhibit severe types of LN, which reinforces the need for early biopsies to detect LN. Key Points• Our findings show that histopathology changes other than lupus nephritis may occur in a significant number of patients with clinical and laboratory signs of novel kidney involvement.• Low-grade proteinuria does not exclude findings of active lupus nephritis that require the start of immunosuppressive therapy.• The study stresses the importance of performing kidney biopsies also in the presence of low-grade proteinuria or when signs of kidney function abnormalities occur.• This is crucial as early detection and prompt initiation of therapy may improve outcomes in lupus nephritis.


  • Open Access

    Urine Galectin-3 binding protein reflects nephritis activity in systemic lupus erythematosus

    by Francesca Faustini, Helena Idborg, Enrico Fuzzi, Anders Larsson, Wen-Rong Lie, Sven Pötzsch, Shinji L Okitsu, Elisabet Svenungsson, Iva Gunnarsson

    Background: Lupus nephritis (LN) is a major and severe organ involvement in systemic lupus erythematosus (SLE), whose diagnosis and treatment necessitate to perform kidney biopsy, which is an invasive procedure. Non-invasive urine biomarkers are an active area of investigation to support LN diagnosis and management. Objective: To investigate the role of urinary galectin-3 binding protein (u-Gal-3BP) as a candidate biomarker of renal disease in biopsy proven LN. Patients and methods: Levels of u-Gal-3BP were investigated in a cross-sectional fashion by ELISA in 270 subjects: 86 LN patients, 63 active SLE patients with no kidney involvement, 73 SLE patients with inactive disease and 48 age and sex-matched population-based controls (PBC). Moreover, urine samples were analysed separately by ELISA for additional markers of kidney pathology: neutrophil gelatinase-associated lipocalin (NGAL), osteopontin (OPN), kidney injury molecule-1 (KIM-1) and galectin-3 (Gal-3). The concentrations of all studied molecules were normalized to urine creatinine levels. In 10 patients, post-treatment levels of the biomarkers were measured. Results: Normalized u-Gal-3BP levels were higher in LN patients compared to the other groups ( p < .0001). Comparing different LN classes, u-Gal-3BP levels were higher among patients with proliferative (class III/IV) and membranous (class V) as compared to mesangial (class II) forms ( p = .04). In proliferative forms, u-Gal-3BP levels correlated with the activity index in renal biopsies (r = 0.42, p = .004). Moreover, in a subset of 10 patients with repeated kidney biopsy and urine sampling before and after induction treatment, a significant decrease of u-Gal-3BP was observed ( p = .03) . Among the other markers, KIM-1 was also able to discriminate LN from the other groups, while NGAL, OPN and Gal-3 could not in this cohort. Conclusion: Given its ability to discriminate LN patients from active non-renal and inactive SLE patients, the observed correlation with the activity index in renal biopsies, and its levels declining following treatment, u-Gal-3BP shows promise as a non-invasive urinary biomarker to help detecting and to monitor renal involvement in SLE patients and should be validated in larger cohorts.


  • Open Access

    Interleukin (IL) 16: a candidate urinary biomarker for proliferative lupus nephritis

    by Aliisa Häyry, Francesca Faustini, Agneta Zickert, Anders Larsson, Timothy B Niewold, Elisabet Svenungsson, Vilija Oke, Iva Gunnarsson

    Objective Lupus nephritis (LN) is a severe manifestation of systemic lupus erythematosus (SLE). The pathogenesis is incompletely understood and diagnostic biomarkers are scarce. We investigated interleukin (IL) 16 as a potential biomarker for LN in a well-characterised cohort of patients with SLE. Methods We measured urinary (u-) and plasma (p-) levels of IL-16 in predefined patient groups using ELISA: LN (n=84), active non-renal SLE (n=63), inactive non-renal SLE (n=73) and matched population controls (n=48). The LN group included patients with recent biopsy-confirmed proliferative (PLN, n=47), mesangioproliferative (MES, n=11) and membranous (MLN, n=26) LN. Renal expression of IL-16 was investigated by immunohistochemistry. Associations between IL-16 measurements and clinical parameters and the diagnostic value for LN were explored. Results p-IL-16 was detected in all investigated cases and high p-IL-16 levels were observed in patients with active SLE. u-IL-16 was detected (dt-u-IL-16) in 47.6% of patients with LN, while only up to 17.8% had dt-u-IL-16 in other groups. In the LN group, 68% of patients with PLN had dt-u-IL-16, while the proportions in the MLN and MES groups were lower (11.5% and 45.5%, respectively). The highest u-IL-16 levels were detected in the PLN group. In the regression model, u-IL-16 levels differentiated PLN from other LN patient subgroups (area under the curve 0.775–0.896, pConclusions We demonstrate that detectable u-IL-16 can differentiate patients with PLN from those with less severe LN subtypes and active non-renal SLE. Our findings suggest that u-IL-16 could be used as a screening tool at suspicion of severe LN. Furthermore, the high IL-16 levels in plasma, urine and kidney tissue imply that IL-16 could be explored as a therapeutic target in SLE.


  • Open Access

    Rituximab in Systemic Lupus Erythematosus: Transient Effects on Autoimmunity Associated Lymphocyte Phenotypes and Implications for Immunogenicity

    by Francesca Faustini, Natalie Sippl, Ragnhild Stålesen, Karine Chemin, Nicky Dunn, Anna Fogdell-Hahn, Iva Gunnarsson, Vivianne Malmström

    B cell abnormalities are common in systemic lupus erythematosus (SLE), and include expansion of double negative (DN) and age-associated-like B cells (ABC-like). We aimed to investigate rituximab (RTX) effects on DN and ABC-like B-cell subsets and, when possible, also secondary effects on T cells. Fifteen SLE patients, fulfilling the ACR 1982 criteria, starting RTX and followed longitudinally up to two years, were analyzed for B- and T- lymphocyte subsets using multicolor flow cytometry. DN were defined as IgD-CD27- and ABC-like as CD11c+CD21- within the DN gate. Additional phenotyping was performed adding CXCR5 in the B-cell panel. Cellular changes were further analyzed in the context of the generation of anti-drug antibodies (ADA) against RTX and clinical information. The SLE patients were mainly females (86.6%), of median age 36.7 (29.8-49.4) years and disease duration of 6.1 (1.6-11.8) years. Within the DN subset, ABC-like (IgD-CD27-CD11c+CD21-) B cell frequency reduced from baseline median level of 20.4% to 11.3% (p=0.03), at early follow-up. The DN B cells were further subdivided based on CXCR5 expression. Significant shifts were observed at the early follow-up in the DN2 sub-cluster (CD11c+CXCR5-), which reduced significantly (-15.4 percentage points, p=0.02) and in the recently described DN3 (CD11c-CXCR5-) which increased (+13 percentage points, p=0.03). SLE patients treated with RTX are at high risk of developing ADA. In our cohort, the presence of ADA at 6 months was associated with lower frequencies of DN cells and to a more pronounced expansion of plasmablasts at early follow-up. The frequency of follicular helper T cells (TFH, CD4+PD-1+CXCR5+) and of peripheral helper T cells (TPH, CD4+PD-1+CXCR5-) did not change after RTX. A sub-cluster of PD-1highCD4+ T cells showed a significant decrease at later follow-up compared to early follow-up (p=0.0039). It is well appreciated that RTX transiently influences B cells. Here, we extend these observations to cell phenotypes which are believed to directly contribute to autoimmunity in SLE. We show early transient effects of RTX on ABC-like memory B cells, later effects on PD-1high CD4+ cells, and possible implications for RTX immunogenicity. Further insight in such effects and their monitoring may be of clinical relevance.


  • Open Access

    First exposure to rituximab is associated to high rate of anti-drug antibodies in systemic lupus erythematosus but not in ANCA-associated vasculitis

    by Francesca Faustini, Nicky Dunn, Nastya Kharlamova, Malin Ryner, Annette Bruchfeld, Vivianne Malmström, Anna Fogdell-Hahn, Iva Gunnarsson

    Background: Anti-drug antibodies (ADAs) can impact on the efficacy and safety of biologicals, today used to treat several chronic inflammatory conditions. Specific patient groups may be more prone to develop ADAs. Rituximab is routinely used for ANCA-associated vasculitis (AAV) and as off-label therapy for systemic lupus erythematosus (SLE), but data on occurrence and predisposing factors to ADAs in these diseases is limited. Objectives: To elucidate the rate of occurrence, and risk factors for ADAs against rituximab in SLE and AAV. Methods: ADAs were detected using a bridging electrochemiluminescent (ECL) immunoassay in sera from rituximab-naïve (AAV; n = 41 and SLE; n = 62) and rituximab-treated (AAV; n = 22 and SLE; n = 66) patients. Clinical data was retrieved from medical records. Disease activity was estimated by the SLE Disease Activity Index-2000 (SLEDAI-2 K) and the Birmingham Vasculitis Activity Score (BVAS). Results: After first rituximab cycle, no AAV patients were ADA-positive compared to 37.8% of the SLE patients. Samples were obtained at a median (IQR) time of 5.5 (3.7–7.0) months (AAV), and 6.0 (5.0–7.0) months (SLE). ADA-positive SLE individuals were younger (34.0 (25.9–40.8) vs 44.3 (32.7–56.3) years, p = 0.002) and with more active disease (SLEDAI-2 K 14.0 (10.0–18.5) vs. 8.0 (6.0–14), p = 0.0017) and shorter disease duration (4.14 (1.18–10.08) vs 9.19 (5.71–16.93), p = 0.0097) compared to ADA-negative SLE. ADAs primarily occurred in nephritis patients, were associated with anti-dsDNA positivity but were not influenced by concomitant use of corticosteroids, cyclophosphamide or previous treatments. Despite overall reduction of SLEDAI-2 K (12.0 (7.0–16) to 4.0 (2.0–6.7), p < 0.0001), ADA-positive individuals still had higher SLEDAI-2 K (6.0 (4.0–9.0) vs 4.0 (2.0–6.0), p = 0.004) and their B cell count at 6 months follow-up was higher (CD19 + % 4.0 (0.5–10.0) vs 0.5 (0.4–1.0), p = 0.002). At retreatment, two ADA-positive SLE patients developed serum sickness (16.7%), and three had infusion reactions (25%) in contrast with one (5.2%) serum sickness in the ADA-negative group. Conclusions: In contrast to AAV, ADAs were highly prevalent among rituximab-treated SLE patients already after the first course of treatment and were found to effect on both clinical and immunological responses. The high frequency in SLE may warrant implementations of ADA screening before retreatment and survey of immediate and late-onset infusion reactions.